khellin has been researched along with Vitiligo in 33 studies
Khellin: A vasodilator that also has bronchodilatory action. It has been employed in the treatment of angina pectoris, in the treatment of asthma, and in conjunction with ultraviolet light A, has been tried in the treatment of vitiligo. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1024)
khellin : A furanochrome in which the basic tricyclic skeleton is substituted at positions 4 and 9 with methoxy groups and at position 7 with a methyl group. A major constituent of the plant Ammi visnaga it is a herbal folk medicine used for various illnesses, its main effect being as a vasodilator.
Vitiligo: A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to evaluate the efficacy of topical khellin the vitiligo macules of one side only were painted in 41 patients with a 2% solution of khellin in acetone and propylene glycol (90 and 10%, respectively) and exposed to sunlight for a period of 4 months with 3 weekly applications and with exposure times up to 90 min." | 9.07 | Photochemotherapy with topical khellin and sunlight in vitiligo. ( Orecchia, G; Perfetti, L, 1992) |
| "The first objective was to evaluate the additional value of combining blister roof transplantation (BRT) with khellin in liposomes and ultraviolet light (KLUV) in the treatment of recalcitrant vitiligo patches." | 7.77 | Treatment of vitiligo with khellin liposomes, ultraviolet light and blister roof transplantation. ( Assen, YJ; Bjerring, P; de Leeuw, J; Martino Neumann, HA; van der Beek, N, 2011) |
| "Twenty-eight patients with vitiligo were treated with a new photochemotherapeutic regimen using khellin, a furanochromone, as photosensitizer, together with ultraviolet A (UVA) irradiation." | 7.67 | Treatment of vitiligo with khellin and ultraviolet A. ( Hönigsmann, H; Ortel, B; Tanew, A, 1988) |
| "Vitiligo is an idiopathic leukoderma often with a progressive course causing destruction of melanocytes." | 6.71 | Treatment of vitiligo with local khellin and UVA: comparison with systemic PUVA. ( Christova, P; Trashlieva, M; Valkova, S, 2004) |
| "Khellin, whose chemical structure closely resembles that of psoralen, is reported to be an efficient drug for treating vitiligo when combined with ultraviolet A irradiation." | 5.06 | Phototherapeutic, photobiologic, and photosensitizing properties of khellin. ( Averbeck, D; Dardalhon, M; Dubertret, L; Hönigsmann, H; Hüppe, G; Morliere, P; Ortel, B; Santus, R, 1988) |
| "Therapy with khellin and UVA irradiation (KUVA) is a therapeutic approach to vitiligo." | 3.69 | Provocation of porphyria cutanea tarda by KUVA-therapy of vitiligo. ( Hölzle, E; Jansen, T; Megahed, M; Plewig, G, 1995) |
| "Twenty-eight patients with vitiligo were treated with a new photochemotherapeutic regimen using khellin, a furanochromone, as photosensitizer, together with ultraviolet A (UVA) irradiation." | 3.67 | Treatment of vitiligo with khellin and ultraviolet A. ( Hönigsmann, H; Ortel, B; Tanew, A, 1988) |
| "Traditionally, the treatment of vitiligo has focused on pharmacologic interventions, but nearly half of all treated patients fail to respond successfully." | 2.48 | Advanced treatment modalities for vitiligo. ( Cohen, GF; Paghdal, KV; Patel, NS, 2012) |
| "The goal of treating vitiligo is to make it less noticeable either by restoring lost pigment or by eliminating remaining pigment." | 1.51 | Functional nutrition as integrated approach in vitiligo management. ( Barygina, V; Di Nardo, V; França, K; Lotti, T; Tirant, M; Valle, Y, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (57.58) | 18.7374 |
| 1990's | 3 (9.09) | 18.2507 |
| 2000's | 2 (6.06) | 29.6817 |
| 2010's | 8 (24.24) | 24.3611 |
| 2020's | 1 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Piquero-Casals, J | 1 |
| Martínez-Martínez, L | 1 |
| Alomar, A | 1 |
| Rozas-Muñoz, E | 1 |
| Juarez, C | 1 |
| Puig, L | 1 |
| Nordlund, JJ | 1 |
| Di Nardo, V | 1 |
| Barygina, V | 1 |
| França, K | 1 |
| Tirant, M | 1 |
| Valle, Y | 1 |
| Lotti, T | 1 |
| Bagherani, N | 1 |
| de Leeuw, J | 1 |
| Assen, YJ | 1 |
| van der Beek, N | 1 |
| Bjerring, P | 1 |
| Martino Neumann, HA | 1 |
| Patel, NS | 1 |
| Paghdal, KV | 1 |
| Cohen, GF | 1 |
| GUNCHE, FF | 1 |
| RADICE, JC | 1 |
| SULZBERGER, MB | 1 |
| LERNER, AB | 1 |
| ELLIOTT, JA | 1 |
| PARISER, H | 1 |
| TAMURA, M | 1 |
| HAMADA, I | 1 |
| VINOKUROV, IN | 1 |
| REZNIKOV, EK | 1 |
| CHERNOVA, PN | 1 |
| TADZHIBAEV, TT | 1 |
| WEISSBERG, R | 1 |
| MIKESOVA, M | 1 |
| Valkova, S | 1 |
| Trashlieva, M | 1 |
| Christova, P | 1 |
| Abdel-Fattah, A | 1 |
| Aboul-Enein, MN | 1 |
| Wassel, GM | 1 |
| El-Menshawi, BS | 1 |
| Jansen, T | 1 |
| Megahed, M | 1 |
| Hölzle, E | 1 |
| Plewig, G | 1 |
| Gambichler, T | 1 |
| Orecchia, G | 1 |
| Perfetti, L | 1 |
| Duschet, P | 1 |
| Schwarz, T | 1 |
| Pusch, M | 1 |
| Gschnait, F | 1 |
| Jung, EG | 1 |
| Fingerhut, W | 1 |
| Ortel, B | 4 |
| Tanew, A | 2 |
| Hönigsmann, H | 4 |
| Morliere, P | 1 |
| Averbeck, D | 1 |
| Dardalhon, M | 1 |
| Hüppe, G | 1 |
| Santus, R | 1 |
| Dubertret, L | 1 |
| Badr Moawad, M | 1 |
| Hinojosa, JA | 1 |
| Pandya, AG | 1 |
| Eun, SH | 1 |
| Lee, JH | 1 |
| Kim, GM | 1 |
| Kim, KH | 1 |
| Bae, JM | 1 |
| Oiso, N | 1 |
| Kawara, S | 1 |
| Kawada, A | 1 |
| Zhang, X | 1 |
| Solomon, LM | 1 |
| Caputo, R | 1 |
| Davis, J | 1 |
| Evans, D | 1 |
| Greenberg, M | 1 |
| Hill, C | 1 |
| Keuer, E | 1 |
| Koya, D | 1 |
| Morgan, N | 1 |
| Pedvis-Leftick, A | 1 |
| Rakhmatov, AB | 1 |
| Chichenina, IV | 1 |
| Raimzhanova, MR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo[NCT03249064] | 28 participants (Actual) | Observational | 2015-10-27 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for khellin and Vitiligo
| Article | Year |
|---|---|
The Medical Treatment of Vitiligo: An Historical Review.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Anthelmintics; Antimalarials; Antimetabolites, A | 2017 |
Advanced treatment modalities for vitiligo.
Topics: Dermabrasion; Humans; Hydroquinones; Khellin; Lasers, Excimer; Low-Level Light Therapy; Melanocytes; | 2012 |
The Importance of Patient Registries in Skin of Color.
Topics: Disease Progression; Humans; Keloid; Quality of Life; Registries; Skin Pigmentation; Vitiligo | 2017 |
Genome-wide association study of skin complex diseases.
Topics: Alopecia; Carcinoma, Basal Cell; Dermatitis, Atopic; Female; Genetic Predisposition to Disease; Geno | 2012 |
4 trials available for khellin and Vitiligo
| Article | Year |
|---|---|
Treatment of vitiligo with local khellin and UVA: comparison with systemic PUVA.
Topics: Adolescent; Adult; Child; Dermatologic Agents; Female; Humans; Khellin; Male; Middle Aged; Pilot Pro | 2004 |
An approach to the treatment of vitiligo by khellin.
Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Khellin; Ma | 1982 |
Photochemotherapy with topical khellin and sunlight in vitiligo.
Topics: Administration, Topical; Adolescent; Adult; Female; Humans; Khellin; Male; Middle Aged; Photochemoth | 1992 |
Phototherapeutic, photobiologic, and photosensitizing properties of khellin.
Topics: Animals; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Cricetinae; Cross-Linking Reagents | 1988 |
25 other studies available for khellin and Vitiligo
| Article | Year |
|---|---|
LRP1/CD91 is highly expressed in monocytes from patients with vitiligo - even after repigmentation.
Topics: Administration, Cutaneous; Adult; Aged; Biomarkers; Case-Control Studies; Chemokine CXCL10; Female; | 2021 |
Functional nutrition as integrated approach in vitiligo management.
Topics: Curcumin; Dietary Supplements; Food, Fortified; Ginkgo biloba; Humans; Khellin; Oxidative Stress; Po | 2019 |
The efficacy of 308 nm UV excimer light as monotherapy and combination therapy with topical khellin 4% and/or tacrolimus 0.1% in the treatment of vitiligo.
Topics: Administration, Topical; Humans; Khellin; Lasers, Excimer; Vitiligo | 2016 |
Treatment of vitiligo with khellin liposomes, ultraviolet light and blister roof transplantation.
Topics: Adult; Aged; Cell Transplantation; Combined Modality Therapy; Female; Humans; Khellin; Liposomes; Ma | 2011 |
[The treatment of vitiligo with visammin].
Topics: Humans; Khellin; Vitiligo | 1954 |
Suntanning-potentiation with oral medication.
Topics: Humans; Khellin; Sunbathing; Sunlight; Suntan; Vitiligo | 1958 |
Methoxsalen in the treatment of vitiligo; an appraisal of the permanency of the repigmentation.
Topics: Humans; Khellin; Methoxsalen; Sunlight; Vitiligo | 1959 |
Critical evaluation of the psoralens.
Topics: Furocoumarins; Humans; Khellin; Vitiligo | 1959 |
[On external meladinin treatment of ordinary vitiligo].
Topics: Humans; Khellin; Methoxsalen; Vitiligo | 1962 |
[Meladine therapy of disseminated forms of vitiligo, alopecia areata and universalis].
Topics: Alopecia; Alopecia Areata; Humans; Khellin; Vitiligo | 1963 |
[TREATMENT OF VITILIGO PATIENTS WITH MELADININE].
Topics: Humans; Khellin; Methoxsalen; Ultraviolet Rays; Vitiligo | 1963 |
[TREATMENT OF VITILIGO BY EXTRACTS OF THE PLANT AMMI MAIUS].
Topics: Ammi; Khellin; Photosensitivity Disorders; Plants, Medicinal; Vitiligo | 1964 |
[Our experiences with the treatment of vitiligo with Meladinin].
Topics: Coumarins; Humans; Khellin; Vitiligo | 1961 |
Provocation of porphyria cutanea tarda by KUVA-therapy of vitiligo.
Topics: Basement Membrane; Blister; Female; Hand Dermatoses; Humans; Khellin; Middle Aged; Photochemotherapy | 1995 |
Vitiligo: phototherapeutic options.
Topics: Humans; Khellin; Photosensitizing Agents; PUVA Therapy; Treatment Outcome; Ultraviolet Therapy; Viti | 1999 |
Marked increase of liver transaminases after khellin and UVA therapy.
Topics: Female; Humans; Khellin; Middle Aged; Transaminases; Ultraviolet Therapy; Vitiligo | 1989 |
Pseudoallergic reaction from Khellin in photochemotherapy of vitiligo: a case report.
Topics: Adult; Drug Eruptions; Female; Humans; Khellin; Photochemotherapy; Vitiligo | 1988 |
Treatment of vitiligo with khellin and ultraviolet A.
Topics: Adolescent; Adult; Child; Erythema; Female; Humans; Khellin; Male; Middle Aged; Photochemotherapy; S | 1988 |
Vitiligo treatment.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; DNA; Huma | 1986 |
Khellin photochemotherapy of vitiligo.
Topics: Humans; Khellin; Photochemotherapy; Vitiligo | 1985 |
Treatment of vitiligo with 1 percent solution of the sodium salt of meladinine using the ionophoresis technique.
Topics: Adolescent; Adult; Child; Female; Humans; Iontophoresis; Khellin; Male; Methods; Middle Aged; Sodium | 1969 |
Vitiligo at a keloid scar: A possible case of Koebner phenomenon.
Topics: Humans; Keloid; Male; Middle Aged; Skin; Thoracic Wall; Vitiligo | 2019 |
The effectiveness of narrowband ultraviolet B on hypertrophic scar in a patient having an isomorphic phenomenon and vitiligo.
Topics: Cicatrix, Hypertrophic; Humans; Keloid; Male; Ultraviolet Therapy; Vitiligo; Young Adult | 2008 |
Miscellaneous dermatoses.
Topics: Acanthosis Nigricans; Adolescent; Athletic Injuries; Dermatomycoses; Female; Granuloma; Humans; Icht | 1978 |
[The development of keloid scars in a female vitiligo patient].
Topics: Adult; Female; Humans; Keloid; Skin; Vitiligo | 1988 |